Reviewer's report

Title: Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain: a cost-effectiveness comparison

Version: 5
Date: 20 May 2014

Reviewer: Gianluca Baio

Reviewer's report:

I think this is a nice, well written and motivated paper. I do have a few comments/requests for changes.

Minor essential revisions
1. Page 10, the authors write: "The ICER is defined as the ratio of the change in costs of an intervention to the change in effects of the intervention". I believe this is slightly incorrect, as the ICER represents the ratio of the differential *population averages* in costs to the differential *population averages* in clinical benefits. This should be emended.

2. Of course, DES can be quite computationally intensive. However, I believe that only using 10 replications of the model may not be sufficient to capture the underlying uncertainty. It would be helpful if the authors were able to extend the number of replications used in their analysis.

3. Page 11: the authors mention "Probabilistic sensitivity analysis" --- I think a lot more detail should be given on this. Is this really a PSA (meaning that the parameters are associated with suitable probability distributions)? If so, what assumptions have been used?

Tables 4-7. The data reported in the tables include some measure of variability (either the sd or the confidence intervals). Have these been used in the model (eg by assuming that the relevant parameters are associated with suitable probability distributions informed by the values reported on the tables)?

Figure 6. It's not clear what the points represent: is each point the average differential costs/QALYs over a set number of replications from the model? If so, how many replications are reported? Also, the label "Cost-Effectiveness Scatterplot (QALYs) is slightly misleading --- technically, a scatterplot consists of two variables.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, and I have assessed the statistics in my report.
**Declaration of competing interests:**

I declare that I have no competing interests